PT-141 (Bremelanotide) vs Argireline
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →Argireline
Argireline (Acetyl Hexapeptide-3) is a widely-used cosmetic peptide that reduces wrinkle depth by inhibiting neurotransmitter release. One of the first 'Botox-like' peptides developed for topical use.
Full details →Side-by-Side Comparison
| Aspect | PT-141 (Bremelanotide) | Argireline |
|---|---|---|
| Mechanism | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. | Inhibits the formation of the SNARE complex required for neurotransmitter release, reducing the intensity of muscle contractions that cause expression lines. |
| Typical Dosage | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. | Topical: 5-10% concentration in serums, applied twice daily. Higher concentrations used in professional treatments. |
| Administration | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. | Topical application to clean skin. Most effective on expression lines (forehead, crow's feet). Consistent use required for visible results. |
| Side Effects | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. | Generally very well-tolerated. Occasional mild irritation or dryness. No systemic absorption at cosmetic doses. |
| Best For |